To further verify the role of NLRP3 inflammasome in obese cardiomyopathy, NLRP3 inflammasome inhibitor MCC950 was administered intraperitoneally to obese mice after 12 weeks of HFD consumption at a dose of 10 mg/kg and day for 12 weeks (Figure S3A). Here, NLRP3 is linked to cardiomyopathy.